Workflow
Surgical Robotics for Minimally Invasive Endovascular Intervention
icon
搜索文档
Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025
GlobeNewswire News Room· 2025-07-23 20:00
ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2025 second quarter on Thursday, August 7, 2025 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis second quarter 2025 financial re ...
Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock
Globenewswire· 2025-07-17 20:32
文章核心观点 - 公司宣布与投资者达成协议,以每股2美元价格出售约1250万美元普通股,所得资金用于加速产品商业化、研发等 [1][2] 融资情况 - 融资由战略行业合作伙伴牵头,部分机构投资者参与 [1] - 融资总收益预计约1250万美元,扣除费用前 [3] - 首次交割约850万美元预计7月18日左右完成,二次交割400万美元预计11月25日前完成,需满足常规交割条件 [3] - 此次发售依据先前提交并生效的S - 3表格上架注册声明的补充招股说明书进行 [4] 资金用途 - 所得资金用于加速产品商业化、研发及其他公司用途 [2] 公司介绍 - 公司是微创血管内介入手术机器人创新领域先驱和全球领导者,使命是为介入实验室开发和提供机器人系统等解决方案 [6] - 其技术已用于治疗美国、欧洲、亚洲等地超15万名患者 [6]